Moving to better COPD care—changes to and challenges for GOLD.
noviembre 12, 2026
COPD care and GOLD 2026: disease activity, exacerbation risk, treatment escalation and multimorbidity in a more proactive approach.
COPD care and GOLD 2026: disease activity, exacerbation risk, treatment escalation and multimorbidity in a more proactive approach.
Astegolimab for COPD was evaluated in the ALIENTO and ARNASA trials to assess its efficacy and safety in patients with frequent exacerbations.
2026 GOLD update: key recommendations for primary care on COPD diagnosis, assessment, prevention, treatment, exacerbations and emerging technologies.